Indinavir

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Indinavir

Examples of brand names: Crixivan [EU; historical, authorisation withdrawn on 26 March 2021]

ATC code: J05AE02

Main use (for orientation): Historically: HIV-1 in adults, combination antiretroviral therapy

Documented research summary

Randomised 14-day study: cannabis-smoking arm n=9 with a small reduction in indinavir Cmax; other pharmacokinetic differences were not significant. Limited short-term evidence; do not extrapolate to CBD or current HIV regimens.

Uncertainties and limitations

Historical CRIXIVAN capsule label, 2012. No claim of current market availability; the studied cannabis-smoking and dronabinol arms are distinguished.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC-containing cannabis/dronabinol, separate study arms – clinically investigated

Finding ID: B0093

Type of result: Context-specific finding; read the limitations

Observation: Small reductions in the cannabis-smoking arm, with a statistically reduced Cmax; the authors expected no short-term clinical consequence.

Mechanism: Pharmacokinetics in a clinical trial

Study type: Randomised placebo-controlled pharmacokinetic study

Context studied: 28 indinavir participants across three study arms; 14 days.

Clinical interpretation: Individual medical / pharmaceutical assessment; do not use as dosage instructions

Limitations and uncertainties: Do not extrapolate to modern HIV medicines or highly concentrated CBD.

Original sources for this finding: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir [EX05]

References and access status

[V2_LABEL_D0448] CRIXIVAN (INDINAVIR SULFATE) CAPSULE [STAT RX USA LLC]

Original source / bibliographic reference

Authors: STAT Rx USA LLC

Year: 2012

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[EX05] The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir

Original source / bibliographic reference

Authors: Kosel BW; Aweeka FT; Benowitz NL; Shade SB; Hilton JF; Lizak PS; Abrams DI

Year: 2002

Source type: Randomised placebo-controlled pharmacokinetic study

DOI: 10.1097/00002030-200203080-00005

PMID: 11872997

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility